Skin cancer in the United States is a large and growing public concern. Non-melanoma skin cancer (NMSC) frequently occurs in sun-exposed areas such as the face. Two procedures that can be used to remove NMSC tumors are standard excision and Mohs surgery. Our study will compare these two surgical procedures for the treatment of facial NMSC skin in terms of cost, effectiveness, and impact on quality of life (QOL). Our goal is to determine which of the two procedures provides the highest cure rate, at the lowest cost while providing the greatest QOL. Issues such as these may be addressed analytically through the use of cost-effectiveness analyses (CEA). CEA are basic and essential tools used for evaluating health care practices. They measure the relative efficiency of one health care strategy as compared to that of the other strategies. Costs, efficacy, and outcomes are vital components of a CEA. CEA identify variables of the health care pathway that are important determinants of cost and/or outcome. Policy makers can then address these variables to convert a health care plan to a more cost-effective one. Our pilot data has provided the cost of the two types of surgical techniques.
The specific aims of the proposed project are two fold: the determination efficiency of the two procedures, and impact the procedures have on QOL. This will be done at Emory University where patients who have undergone Mohs surgery will be asked to complete a questionnaire about the impact the scars from a Mohs procedure have on their quality of life. Understanding that CEA compare both costs and outcomes, we hypothesize that Mohs surgery by is more cost-effective and provides greater QOL outcomes than standard surgical excision for facial NMSC.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Arbiser, Jack L; Bonner, Michael Y; Gilbert, Linda C (2017) Targeting the duality of cancer. NPJ Precis Oncol 1:
Pleniceanu, Oren; Shukrun, Racheli; Omer, Dorit et al. (2017) Peroxisome proliferator-activated receptor gamma (PPAR?) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target EMBO Mol Med 9:508-530
Díaz, Begoña; Ostapoff, Katherine T; Toombs, Jason E et al. (2016) Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. Oncotarget 7:51569-51580
Laidlaw, Kamilla M E; Berhan, Samuel; Liu, Suhu et al. (2016) Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. Oncotarget 7:51651-51664
Bhandarkar, Sulochana S; Lanka, Padmavathy; Lanka, Lakshmana Rao et al. (2016) Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions. Exp Dermatol 25:479-80
Costa, Adilson; Bonner, Michael Yi; Arbiser, Jack L (2016) Use of Polyphenolic Compounds in Dermatologic Oncology. Am J Clin Dermatol 17:369-85
Bonner, Michael Y; Karlsson, Isabella; Rodolfo, Monica et al. (2016) Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget 7:12857-68
Arbiser, Jack L; Bonner, Michael Y (2016) Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. J Invest Dermatol 136:564-566
Arbiser, Jack L (2014) PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol 134:600-602
Spence-Shishido, Allyson; Carr, Christopher; Bonner, Michael Y et al. (2013) In vivo Gram staining of tinea versicolor. JAMA Dermatol 149:991-2

Showing the most recent 10 out of 131 publications